Payment overview · 2025
General Payments
$143.33
7 reported records · 5 companies
Healthcare provider profile · identity verified
Anil Matta, M.D.
Allopathic & Osteopathic Physicians|Hospitalist · NATCHITOCHES, LA · NPI 1871795674
Verified facts
What the public records show
CMS Open Payments records show Anil Matta, M.D. received $143.33 in general payments during 2025 across 7 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 35.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.42 | 35.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.62 | 26.2% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.13 | 14.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.64 | 13.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.52 | 10.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $143.33 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.42 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.62 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 493 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 337 | 75 |
| Gabapentin | Gabapentin | 301 | 68 |
| Famotidine | Famotidine | 282 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 59 |
| Meloxicam | Meloxicam | 266 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 48 |
| Furosemide | Furosemide | 209 | 49 |
| Metformin Hcl | Metformin Hcl | 197 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 44 |
| Carvedilol | Carvedilol | 163 | 35 |
| Potassium Chloride | Potassium Chloride | 160 | 41 |
| Trazodone Hcl | Trazodone Hcl | 160 | 33 |
| Omeprazole | Omeprazole | 158 | 29 |
| Montelukast Sodium | Montelukast Sodium | 153 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 35 |
| Glipizide | Glipizide | 145 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 140 | 29 |
| Losartan Potassium | Losartan Potassium | 138 | 31 |
| Eliquis | Apixaban | 129 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 24 |
| Ozempic | Semaglutide | 105 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 97 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 34 |
| Ezetimibe | Ezetimibe | 92 | 20 |
| Tramadol Hcl | Tramadol Hcl | 90 | 47 |
| Simvastatin | Simvastatin | 89 | 19 |
| Allopurinol | Allopurinol | 88 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 86 | 77 |
| Prednisone | Prednisone | 78 | 59 |
| Farxiga | Dapagliflozin Propanediol | 75 | 14 |
| Lisinopril | Lisinopril | 75 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 23 |
| Januvia | Sitagliptin Phosphate | 64 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | suppressed |
| Pregabalin | Pregabalin | 58 | 15 |
| Mirtazapine | Mirtazapine | 52 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 15 |
| Linzess | Linaclotide | 50 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 49 | 11 |
| Clonidine Hcl | Clonidine Hcl | 48 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 12 |
| Lovastatin | Lovastatin | 47 | suppressed |
| Baclofen | Baclofen | 46 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 25 |
| Sertraline Hcl | Sertraline Hcl | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 16 |
| Mounjaro | Tirzepatide | 43 | 12 |
| Glimepiride | Glimepiride | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Nifedipine Er | Nifedipine | 42 | 14 |
| Alprazolam | Alprazolam | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Sucralfate | Sucralfate | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 31 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 30 | 27 |
| Multaq | Dronedarone Hcl | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 29 | 20 |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 28 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 24 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Rivastigmine | Rivastigmine | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Novolin R | Insulin Regular, Human | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Fluconazole | Fluconazole | 17 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Vardenafil Hcl | Vardenafil Hcl | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $143.33 · 7 records | Bayer Healthcare Pharmaceuticals Inc. | Cologuard Collection Kit, Kerendia, NUZYRA, OTEZLA, REPATHA, Veozah, XHANCE | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error